Clinical trial NCT05486117: Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema
Official title: A Phase 1 Clinical Trial to Evaluate the Pharmacokinetics of Twice-daily Applications of Delgocitinib Cream 20 mg/g for 1 Week in Adult Subjects With Moderate to Severe Chronic Hand Eczema.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Chronic Hand Eczema
Lead sponsor: LEO Pharma
Sponsor class: INDUSTRY
First posted: 2022-08-03
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the trial is to test how much delgocitinib enters the body over a given time period after application of delgocitinib cream in patients with moderate to severe hand eczema.

Delgocitinib is a cream that suppresses specific processes in the body's response to diseases like CHE, such as inflammation. Everyone in the trial will use delgocitinib cream.

The trial will last up to 7 weeks and there will be 6 visits and a phone call. There will be a screening period of up to 4 weeks, a treatment period (with blood sampling) of 11 days and a safety follow-up phone call 11 days after the last visit.


Eligibility criteria: Inclusion Criteria:

* Age 18 years or above at screening.
* Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months.
* Disease severity graded as moderate to severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 3 or 4).
* Subjects who have a documented recent history of inadequate response to treatment with topical corticosteroids (TCS) (at any time within 1 year before the screening visit) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks).
* Subjects adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens.

Exclusion Criteria:

* Concurrent skin diseases on the hands, e.g. tinea manuum.
* Active atopic dermatitis (AD) requiring medical treatment in regions other than the hands and feet.
* Active psoriasis on any part of the body.
* Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body.
* Clinically significant infection (e.g. impetiginised hand eczema) on the hands.
* Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), immunomodulating drugs, retinoids (e.g. alitretinoin), or corticosteroids within 28 days prior to baseline (steroid eyedrops and inhaled or intranasal steroids corresponding to up to 1 mg prednisolone for allergic conjunctivitis, asthma, or rhinitis are allowed).
* Use of tanning beds, phototherapy (e.g. ultraviolet B \[UVB\], ultraviolet A1 \[UVA1\], psoralen ultraviolet A \[PUVA\]), or bleach baths on the hands within 28 days prior to baseline.
* Cutaneously applied treatment with immunomodulators (e.g. phosphodiesterase 4 \[PDE-4\] inhibitors, pimecrolimus, tacrolimus) or TCS on the hands within 14 days prior to baseline.
* Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline.
* Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline.

Primary outcomes:
measure: Area under the concentration-time curve 0-12 hours post dose at Day 1 and Day 8 (AUC0-12).
timeFrame: 0-12 hours post dose at Day 1 and Day 8
measure: Maximum observed concentration (Cmax) at Day 1 and at Day 8 (0-12 hours post-dose).
timeFrame: Day 1 and at Day 8 (0-12 hours post-dose)
Secondary outcomes:
measure: Time to reach maximum observed concentration (tmax) at Day 1 and Day 8 (0-12 hours post-dose).
timeFrame: Day 1 and Day 8 (0-12 hours post-dose).
measure: Terminal elimination half-life (t1/2) at Day 8.
timeFrame: Day 8.
measure: Number of treatment-emergent adverse events (AEs) from baseline to Day 22 per subject.
timeFrame: Baseline to Day 22
Other outcomes:
Locations:
city: Hamburg
country: Germany
facility: LEO Investigational Site
Study officials:
affiliation: LEO Pharma
name: Medical Expert
role: STUDY_DIRECTOR
References: